Source link : https://www.newshealth.biz/health-news/glp-1-prescribing-decisions-compounded-or-brand-name/
The decision to prescribe a compounded or brand-name glucagon-like peptide 1 (GLP-1) medication for obesity treatment was never simple, but recent developments have complicated it further. Both Eli Lilly and Company and Novo Nordisk have asked the US Food and Drug Administration (FDA) to place their GLP-1 medications, tirzepatide and semaglutide, on its Demonstrable Difficulties […]
Author : News Health
Publish date : 2024-11-14 11:02:17
Copyright for syndicated content belongs to the linked Source.